Latest filings (excl ownership)
6-K
Result of Agm
11 Apr 24
6-K
Astrazeneca Increases 2024 Dividend by 7%
11 Apr 24
6-K
Enhertu Approved In Us for HER2+ Solid Tumours
8 Apr 24
6-K
Imfinzi Improved Os & PFS In Limited-stage SCLC
5 Apr 24
6-K
Total Voting Rights
2 Apr 24
6-K
Voydeya Approved In Us
2 Apr 24
6-K
Fda Accepts Dato-dxd Bla for Breast Cancer
2 Apr 24
6-K
Ultomiris Approved In the Us for Nmosd
25 Mar 24
DFAN14A
Additional proxy materials by non-management
19 Mar 24
F-3ASR
Automatic shelf registration (foreign)
19 Mar 24
6-K
Current report (foreign)
19 Mar 24
6-K
Astrazeneca to Acquire Amolyt
14 Mar 24
6-K
Director/pdmr Shareholding
12 Mar 24
6-K
Current report (foreign)
7 Mar 24
6-K
Notice of Agm
7 Mar 24
6-K
Director/pdmr Shareholding
6 Mar 24
6-K
Director/pdmr Shareholding
6 Mar 24
CERT
Certification of approval for exchange listing
6 Mar 24
8-A12B
Registration of securities on exchange
5 Mar 24
6-K
Ema Validates Dato-dxd Maas for NSQ NSCLC and BC
4 Mar 24
6-K
Total Voting Rights
1 Mar 24
6-K
Current report (foreign)
26 Feb 24
6-K
Voydeya Recommended for Eu Approval
26 Feb 24
424B2
Prospectus for primary offering
23 Feb 24
6-K
Astrazeneca Prices a $5BN Bond Offering
22 Feb 24
6-K
Current report (foreign)
22 Feb 24
6-K
Director/pdmr Shareholding
22 Feb 24
FWP
Free writing prospectus
21 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
21 Feb 24
424B2
Prospectus for primary offering
21 Feb 24
6-K
Filing of Form 20-F with Sec
21 Feb 24
S-8
Registration of securities for employees
20 Feb 24
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
20 Feb 24
20-F
2023 FY
Annual report (foreign)
20 Feb 24
6-K
Current report (foreign)
20 Feb 24
6-K
Annual Financial Report
20 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
20 Feb 24
6-K
Current report (foreign)
20 Feb 24
6-K
Astrazeneca Completes Acquisition of Icosavax
20 Feb 24
6-K
Tagrisso Plus Chemo Approved In Us for Lung Cancer
20 Feb 24
Latest ownership filings
SC 13G/A
ADC Therapeutics SA
12 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13D/A
Cellectis S.A.
16 Nov 23
144
Notice of proposed sale of securities
13 Nov 23
SC 13D
Cellectis S.A.
9 Nov 23
11-K
Annual report of employee stock purchases
28 Jun 23
SC 13G/A
Aridis Pharmaceuticals, Inc.
10 Feb 23
SC 13G/A
PIERIS PHARMACEUTICALS, INC.
10 Feb 23
SC 13G/A
BlackRock Inc.
24 Jan 23
SC 13G
BlackRock Inc.
8 Jul 22
11-K
Annual report of employee stock purchases
28 Jun 22
SC 13G/A
BlackRock Inc.
7 Feb 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
4 Feb 22
SC 13G
Aridis Pharmaceuticals, Inc.
27 Jul 21
11-K
Annual report of employee stock purchases
29 Jun 21
SC 13G
PIERIS PHARMACEUTICALS, INC.
8 Apr 21
4
Viela Bio, Inc.
16 Mar 21
SC 13G
ADC Therapeutics SA
10 Feb 21
SC 13G/A
Moderna, Inc.
10 Feb 21
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
3 Feb 21
SC 13G/A
BlackRock Inc.
29 Jan 21
11-K
Annual report of employee stock purchases
26 Jun 20
4
Aevi Genomic Medicine, Inc.
7 Feb 20
3
Aevi Genomic Medicine, Inc.
7 Feb 20
SC 13D
Aevi Genomic Medicine, Inc.
7 Feb 20
SC 13G/A
Beneficial ownership report (amended)
5 Feb 20
SC 13G
Viela Bio, Inc.
30 Jan 20
SC 13G/A
Astrazeneca PLC
27 Jan 20
SC 13D
Innate Pharma SA
25 Oct 19
4
Viela Bio, Inc.
9 Oct 19
3/A
Viela Bio, Inc.
9 Oct 19
3
Viela Bio, Inc.
2 Oct 19
11-K
Annual report of employee stock purchases
27 Jun 19
SC 13G/A
Astrazeneca PLC
12 Feb 19
SC 13G/A
Beneficial ownership report (amended)
4 Feb 19
SC 13G
Moderna, Inc.
30 Jan 19
SC 13D
PhaseBio Pharmaceuticals Inc
29 Oct 18
4
PhaseBio Pharmaceuticals Inc
24 Oct 18
3
PhaseBio Pharmaceuticals Inc
17 Oct 18
SC 13D/A
Entasis Therapeutics Holdings Inc.
12 Oct 18